| 梅玉霞,付 伟,沈毅韵,刘小敏,庄 承.黄芪注射液联合布地奈德治疗支气管哮喘急性发作期患者的疗效及对免疫功能的影响[J].现代生物医学进展英文版,2018,(12):2329-2333. |
| 黄芪注射液联合布地奈德治疗支气管哮喘急性发作期患者的疗效及对免疫功能的影响 |
| Curative Effect of Astragalus Injection Combined with Budesonide in Bronchial Asthma Patients During Acute Attack Stage and its Effect on Immune Function |
| Received:October 31, 2017 Revised:November 25, 2017 |
| DOI：10.13241/j.cnki.pmb.2018.12.027 |
| 中文关键词: 黄芪注射液 布地奈德 支气管哮喘 急性发作期 免疫功能 |
| 英文关键词: Astragalus injection Budesonide Bronchial asthma Acute attack stage Immune function |
| 基金项目:上海市中医薄弱领域专科建设项目（BRZK2016008） |
|
| Hits: 476 |
| Download times: 247 |
| 中文摘要: |
| 摘要 目的：探讨黄芪注射液联合布地奈德治疗支气管哮喘急性发作期患者的疗效及对免疫功能的影响，为临床用药提供依据。方法：选取2016年2月至2017年2月在我院接受治疗的94例支气管哮喘急性发作期患者作为研究对象，根据治疗方式将患者分为布地奈德组（n=46）与联合组（n=48）。布地奈德组患者给予布地奈德经口吸入治疗，联合组患者在此基础上联用黄芪注射液治疗，两组均治疗2周。分别于治疗前和治疗2周后测量患者第一秒用力呼气容积占预计值百分比（FEV1%）和第一秒用力呼气容积占用力肺活量百分比（FEV1/FVC），测定患者血清白细胞介素-4（IL-4）、白细胞介素-6（IL-6）、白细胞介素-8（IL-8）、白细胞介素-17（IL-17）和肿瘤坏死因子-α（TNF-α）水平，并检测所有患者的CD3++、CD4+和CD8+，计算CD4+/CD8+。比较两组患者治疗2周后的疗效。结果：治疗2周后，两组患者FEV1%、FEV1/FVC均明显上升，且联合组的FEV1%、FEV1/FVC明显高于布地奈德组（P<0.05）。治疗2周后，两组患者IL-4、IL-6、IL-8、IL-17及TNF-α水平均明显下降，且联合组的IL-4、IL-6、IL-8、IL-17及TNF-α水平明显低于布地奈德组P<0.05）。治疗2周后，两组患者的CD3+、CD4+以及CD4+/CD8+均明显上升，且联合组的CD3+、CD4+以及CD4+/CD8+明显高于布地奈德组（P<0.05）。联合组总有效率为95.83%，明显高于布地奈德组的82.61%（P<0.05）。结论：黄芪注射液联合布地奈德对支气管哮喘急性发作期患者疗效显著，能明显改善患者肺功能和炎性指标，并能明显提高患者免疫功能，值得在临床上推广应用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical effect of astragalus injection combined with budesonide in acute attack of bronchial asthma and its effect on immune function, in order to provide the basis for clinical medication. Methods: 94 cases of bronchial asthma patients during acute attack stage who were treated in our hospital from February 2016 to February 2017 were selected as sub- jects, and they were divided into budesonide group (n=46) and combination group (n=48) according to the treatment they received. Budesonide group was treated with budesonide oral inhalation, combination group was treated with astragalus injection on this basis, and the two groups were given treatment for two weeks. Before treatment and 2 weeksafter treatment, the percentage of forced expiratory vol- ume in the first second in predicted value (FEV1%) and the percentage of forced expiratory volume in the first second in forced vital ca- pacity (FEV1/FVC) of all the patients were detected, the levels of serum interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-8 (IL-8), in- terleukin-17 (IL-17) and tumor necrosis factor-α (TNF-α) in patients were detected, CD3+, CD4+ and CD8+ were detected in all patients, and CD4+/CD8+ were calculated. The curative effects of two groups were compared 2 weeksafter treatment. Results: At 2 week safter treatment, the FEV1%, FEV1/FVC of the two groups were both increased significantly, and the FEV1% and FEV1/FVC of the combina- tion group were significantly higher than that in the budesonide group (P<0.05). At 2 weeksafter treatment, the levels ofIL-4, IL-6, IL-8, IL-17 and TNF-α in the two groups were both decreased significantly, and the levels ofIL-4, IL-6, IL-8, IL-17 and TNF-α in the combina- tion group were significantly lower than that in the budesonide group (P<0.05). At 2 week safter treatment, the CD3+, CD4+ and CD4+/CD8+ in the two groups were both increased significantly, and the CD3+, CD4+ and CD4+/CD8+ in the combination group were significantly higher than that in the budesonide group (P<0.05). The total effective rate of combination group was 95.83%, which was sig- nificantly higher than 82.61% of budesonide group (P<0.05). Conclusion: Astragalus injection combined with budesonide has a signifi- cant curative effect on bronchial asthma patients during acute attack stage, it can significantly improve the patient's lung function and in- flammatory indicators, and can significantly improve the immune function of patients, which is worthy of clinical application. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
